Japan Sets Conflict Rules For Outside Drug Reviewers
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Pharmaceuticals and Medical Devices Agency's advisory council decided Oct. 1 to formally introduce conflict-of-interest prevention rules, including a cap on consultation and other fees that PMDA-registered outside experts receive from pharmaceutical manufacturers